What is the recommended Syn-Ake dosage?

Syn-Ake dosing varies by experience level. Beginners typically start at 2mg daily, moderate users at 4mg 2x daily, and aggressive protocols use 6mg 2x daily.

How do you reconstitute Syn-Ake?

Syn-Ake comes as a pre-filled device — no reconstitution needed.

What is the half-life of Syn-Ake?

The half-life of Syn-Ake is Unknown (topical peptide — no systemic PK data available). This determines how frequently you need to dose for consistent blood levels.

Syn-Ake

Q: What are the side effects of Syn-Ake?

Generally well-tolerated as a topical cosmeceutical ingredient. Clinical studies report no significant adverse events at standard 4% concentrations. Rare cases of mild, temporary skin irritation, slight redness, or tingling sensation at the application site may occur, particularly in individuals with sensitive skin or compromised skin barrier. Allergic contact dermatitis is theoretically possible but has not been reported at clinically significant rates. No systemic side effects are expected due to minimal transdermal absorption — the peptide acts locally within the upper skin layers without reaching systemic circulation. The EWG Skin Deep database rates this ingredient as low risk for cancer, allergies, immunotoxicity, and developmental/reproductive toxicity.

Anti-AgingTopicalResearchGrade AUnknown (topical peptide — no systemic PK data available) half-life

Anti-WrinkleNeuromuscularTopical PeptideCosmeceuticalSnake Venom Mimetic12 weeks on / 2 weeks off

Benefits

Relaxes facial muscles through competitive antagonism of nicotinic acetylcholine receptors, reducing expression lines

Reduces wrinkle depth by up to 52% after 28 days at 4% concentration in manufacturer studies

Provides rapid onset anti-wrinkle effects — measurable muscle relaxation within minutes of application

Non-invasive topical alternative to botulinum toxin injections for expression line management

Demonstrates antioxidant activity through dose-dependent free radical scavenging (DPPH assay)

Low molecular weight (495.58 Da) enables effective skin penetration without lipid conjugation

Fully reversible mechanism of action with no permanent alteration of neuromuscular function

Well-tolerated with no significant adverse events reported in clinical studies

Half-Life

Unknown

Route

Topical

Frequency

Daily

Vial Sizes

5mg, 10mg

BAC Water

Pre-filled

Safety Grade

Grade A

Open Syn-Ake Dosage Calculator

Calculate exact syringe units for your vial and dose

About Syn-Ake

Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate, Tripeptide-3) is a synthetic tripeptide engineered to mimic the paralytic action of Waglerin-1, a 22-amino-acid peptide found in the venom of the Temple Pit Viper (Tropidolaemus wagleri). The peptide functions as a competitive antagonist of the muscular nicotinic acetylcholine receptor (mnAChR), specifically binding to the epsilon subunit to block acetylcholine from activating the receptor. This prevents sodium ion channel opening, blocks nerve excitation transmission, and induces localized muscle relaxation — a mechanism analogous to botulinum toxin but achieved through topical application rather than injection. In vitro experiments using cultured muscle cells demonstrated that a 0.025% concentration of Syn-Ake reduced the muscle cell contraction rate by 36% within one minute and by 82% after two hours, with the effect being fast-acting, long-lasting, and fully reversible. In a manufacturer-sponsored clinical study of 45 subjects applying a 4% Syn-Ake cream to the forehead, wrinkle depth was reduced by up to 52% after 28 days of daily use. An independent three-month, single-center clinical study (Trookman et al. 2009) evaluated a formulation containing a Waglerin-1-mimicking peptide in 37 women aged 33-45 with periocular and perioral wrinkles, demonstrating statistically significant wrinkle reduction at all timepoints (p <= 0.0003), with 83% of subjects rating satisfaction as excellent or good. The peptide's low molecular weight (495.58 Da, below the 500 Da skin penetration threshold) enables passage through the stratum corneum without requiring lipid conjugation. In silico and in vitro analyses (Gok et al. 2024) confirmed additional antioxidant properties through DPPH radical scavenging, strong binding affinity to SIRT1 (-9.32 kcal/mol) and MMP-13 receptors, and a favorable safety profile based on cytotoxicity and genotoxicity assessments. A 2020 review in Frontiers in Chemistry noted that while manufacturer data is compelling, independent peer-reviewed clinical studies on Tripeptide-3 specifically remain limited. The Cosmetic Ingredient Review process has not flagged safety concerns, and the EWG Skin Deep database rates the ingredient as low risk across all toxicity categories. Syn-Ake is not FDA-approved for any medical indication and is classified as a cosmeceutical research ingredient with strong in vitro evidence and moderate clinical evidence.

Who Should Consider Syn-Ake

Adults over 30 seeking to reduce expression lines and dynamic wrinkles without injections
Individuals looking for a topical botox-like alternative for forehead and crow's feet lines
Skincare enthusiasts building multi-peptide anti-aging protocols targeting neuromuscular relaxation
People with moderate expression lines who want to delay or supplement botulinum toxin treatments
Those seeking a non-invasive, reversible approach to facial muscle relaxation for wrinkle prevention

How Syn-Ake Works

Syn-Ake functions as a competitive antagonist of the muscular nicotinic acetylcholine receptor (mnAChR), mimicking the pharmacological action of Waglerin-1 from Temple Pit Viper venom. The tripeptide binds to the epsilon subunit of the mnAChR at the neuromuscular junction, directly competing with acetylcholine for the receptor binding site. When Syn-Ake occupies the receptor, it prevents acetylcholine from triggering sodium ion channel opening, thereby blocking the depolarization wave that initiates muscle contraction. The cascade is: receptor blockade → prevention of sodium influx → inhibition of motor endplate depolarization → failure of excitation-contraction coupling → localized muscle relaxation. Unlike botulinum toxin (which irreversibly cleaves SNARE complex proteins to prevent acetylcholine vesicle release presynaptically), Syn-Ake acts postsynaptically through reversible competitive binding, meaning muscle function returns fully once the peptide dissociates from the receptor. This reversibility is a key safety feature. In cultured muscle cells, 0.025% Syn-Ake reduced contraction frequency by 82% within 2 hours. The relaxation of repetitively contracting facial muscles (frontalis, orbicularis oculi, corrugator supercilii) reduces the mechanical stress on overlying skin that deepens expression lines over time. In silico studies also demonstrate strong binding to SIRT1 (a sirtuin deacetylase involved in cellular longevity pathways) and matrix metalloproteinases (MMP-1, MMP-8, MMP-13), suggesting possible secondary mechanisms involving collagen degradation inhibition and cellular stress response modulation. The peptide also exhibits concentration-dependent antioxidant activity via free radical scavenging, which may contribute to protection against oxidative skin aging.

What to Expect

Minutes to hours

Subtle smoothing may be noticed immediately after application due to serum vehicle hydration. In vitro data shows 36% muscle contraction reduction within 1 minute and 82% within 2 hours, though topical onset in vivo is slower due to skin penetration time.

Week 1-2

Peptide begins accumulating in the upper skin layers with twice-daily application. Some users report a softening of fine surface expression lines. Full neuromuscular effects are building as steady-state skin concentrations are approached.

Weeks 2-4

Measurable wrinkle reduction becomes apparent. The manufacturer 28-day study reported up to 52% improvement in forehead wrinkle depth at this timepoint. Expression lines around the eyes and mouth begin to visibly soften.

Weeks 4-12

Continued improvement in wrinkle depth and skin smoothness. Clinical studies show sustained significant results (p <= 0.0003) through month 3. Deeper expression lines show gradual improvement as sustained muscle relaxation allows the skin to recover from chronic mechanical creasing.

After stopping

Effects are not permanent. Because Syn-Ake works through reversible receptor binding, muscle contraction returns to normal within 1-2 weeks after discontinuation. Wrinkle depth gradually returns toward baseline as facial muscles resume habitual expression patterns.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	2mg	Daily
Moderate	4mg	2x Daily
Aggressive	6mg	2x Daily

Note: Topical neuromuscular anti-aging peptide also known as Tripeptide-3 or Dipeptide Diaminobutyroyl Benzylamide Diacetate (CAS 823202-99-9). Synthetic biomimetic of Waglerin-1 from the Temple Pit Viper (Tropidolaemus wagleri). Molecular weight 495.58 Da. Formula: C23H37N5O7. Sequence: beta-Ala-Pro-Dab-NH-benzyl (diacetate salt). Developed by Pentapharm Ltd (now DSM-Firmenich). Standard concentration in commercial formulations is 4% in topical serums and creams. Dosing tiers above reflect approximate mg of active peptide per topical application. Apply to clean, dry skin on expression-line-prone areas (forehead, periorbital, perioral).

How to Inject Syn-Ake

Apply a thin layer of Syn-Ake serum or cream (4% active concentration is standard) to clean, dry skin on expression-line-prone areas — forehead, crow's feet (periorbital region), frown lines (glabellar area), and perioral wrinkles. Use morning and evening before moisturizer. Allow 2-3 minutes for absorption before layering other products. For enhanced anti-wrinkle results, combine with SNAP-8 (which targets the presynaptic SNARE complex for complementary neuromuscular inhibition) and/or Matrixyl (for collagen stimulation). Compatible with hyaluronic acid, niacinamide, and vitamin C serums. Avoid applying immediately after aggressive chemical exfoliants (high-concentration AHAs/BHAs or TCA peels) as a compromised skin barrier may alter absorption. Do not apply to broken, actively inflamed, or sunburned skin.

Cycling Protocol

On Period

12 weeks

Off Period

2 weeks

Apply twice daily for 12 weeks to achieve full wrinkle-reducing effect. Manufacturer studies report significant results at 28 days, with continued improvement through 12 weeks. A 2-week break is optional — no receptor desensitization or tachyphylaxis has been reported with continuous use. The reversible competitive binding mechanism means effects diminish gradually over 1-2 weeks after discontinuation as receptor occupancy decreases. Long-term continuous use is commonly practiced in cosmeceutical regimens.

Pharmacokinetics

Half-Life

0min

Bioavailability

Topical: <1% systemic absorption; local skin penetration enabled by MW < 500 Da

Tmax

Not applicable (topical, non-systemic). In vitro muscle relaxation onset within 1-2 minutes; peak effect at ~2 hours.

Data Confidence

low

Source: No systemic pharmacokinetic data available. Syn-Ake is a topical cosmeceutical peptide with a molecular weight of 495.58 Da that acts locally within the skin. Its small size enables stratum corneum penetration but no published studies report systemic Cmax, AUC, or elimination half-life. The peptide exerts its effects through local receptor binding in the upper dermal layers without significant systemic absorption.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Generally well-tolerated as a topical cosmeceutical ingredient. Clinical studies report no significant adverse events at standard 4% concentrations. Rare cases of mild, temporary skin irritation, slight redness, or tingling sensation at the application site may occur, particularly in individuals with sensitive skin or compromised skin barrier. Allergic contact dermatitis is theoretically possible but has not been reported at clinically significant rates. No systemic side effects are expected due to minimal transdermal absorption — the peptide acts locally within the upper skin layers without reaching systemic circulation. The EWG Skin Deep database rates this ingredient as low risk for cancer, allergies, immunotoxicity, and developmental/reproductive toxicity.

Contraindications

Known allergy or hypersensitivity to dipeptide diaminobutyroyl benzylamide diacetate or any component amino acid
Active skin infections, open wounds, or severe dermatitis at intended application sites
Myasthenia gravis or other neuromuscular junction disorders (theoretical risk of exacerbating muscle weakness)
Concurrent use of botulinum toxin injections in the same area (additive neuromuscular blockade, consult physician)
Pregnancy or breastfeeding (no safety data available for this population)
Children under 18 (insufficient safety data)

Drug Interactions

Botulinum toxin injections (Botox, Dysport) — potential additive neuromuscular relaxation when applied to the same facial area; consult dermatologist before combining
SNAP-8 (Acetyl Octapeptide-3) — complementary mechanism (presynaptic SNARE inhibition vs. postsynaptic receptor blockade); combination is commonly used and generally well-tolerated
Topical retinoids (tretinoin, adapalene) — may increase transient skin sensitivity when layered simultaneously; apply at separate times of day
High-concentration chemical peels (glycolic acid >20%, TCA peels) — compromised skin barrier after peeling may alter peptide absorption; wait 48-72 hours post-peel before resuming
Aminoglycoside antibiotics — theoretical concern as aminoglycosides can potentiate neuromuscular blockade; clinical significance for topical peptide is likely negligible